Share Email Print
cover

Proceedings Paper

Cardiovascular photodynamic therapy: state of the art
Author(s): Kathryn W. Woodburn; Stanley G. Rockson
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy (PDT) has been used traditionally for oncologic and ophthalmic indications. In addition, the enormous potential for the use of PDT agents in cardiovascular diseases is currently being translated into reality. Preclinical studies with various photosensitizers have demonstrated reduction in atheromatous plaque and prevention of intimal hyperplasia. With recent advances in light-based vascular devices and laser diode technology, the clinical use of cardiovascular photodynamic therapy is even more likely. Two photosensitizers, 5-aminolevulinic acid (ALA) and AntrinR (motexafin lutetium) Injection, are under clinical evaluation with many other agents in preclinical testing. Here, preclinical studies are reviewed and the clinical viability of cardiovascular photodynamic therapy is discussed.

Paper Details

Date Published: 17 May 2000
PDF: 9 pages
Proc. SPIE 3907, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems X, (17 May 2000); doi: 10.1117/12.386300
Show Author Affiliations
Kathryn W. Woodburn, Pharmacyclics, Inc. (United States)
Stanley G. Rockson, Stanford Univ. School of Medicine (United States)


Published in SPIE Proceedings Vol. 3907:
Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems X
R. Rox Anderson; Kenneth Eugene Bartels; Lawrence S. Bass; C. Gaelyn Garrett; Kenton W. Gregory; Nikiforos Kollias; Harvey Lui; Reza S. Malek; George M. Peavy; Hans-Dieter Reidenbach; Lou Reinisch; David S. Robinson; Lloyd P. Tate; Eugene A. Trowers; Timothy A. Woodward; Kenton W. Gregory; Eugene A. Trowers; Timothy A. Woodward; David S. Robinson; Hans-Dieter Reidenbach; Kenneth Eugene Bartels; Lloyd P. Tate; George M. Peavy; Lou Reinisch; C. Gaelyn Garrett; Reza S. Malek, Editor(s)

© SPIE. Terms of Use
Back to Top